Extension Payment Sample Clauses

Extension Payment. Subject to the full execution and delivery of this Amendment, Buyer shall fund to MFG an additional payment on account of Purchase Price of up to ▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇ Dollars (US$2,500,000.00) (the “Extension Payment”; the Extension Payment and the Additional Deposit ▇▇▇▇▇▇▇ Money, collectively the “Extension ▇▇▇▇▇▇▇ Money”) in installments as follows: (a) Seven Hundred Fifty Thousand United States Dollars (US$750,000.00) on or before July 1, 2013, if the Closing has not previously occurred; (b) Seven Hundred Fifty Thousand United States Dollars (US$750,000.00) on or before July 15, 2013, if the Closing has not previously occurred; (c) Five Hundred Thousand United States Dollars (US$500,000.00) on or before July 30, 2013, if the Closing has not previously occurred; and (d) Five Hundred Thousand United States Dollars (US$500,000.00) on or before August 7, 2013, if the Closing has not previously occurred; provided, however, that any amount of the Extension Payment that remains unpaid as of the date of Buyer’s delivery of the Closing Notice to Lender and Owner (regardless of when otherwise due), if any, shall be funded by Buyer to MFG on the date of Buyer’s delivery of such Closing Notice.

Extension Payment. The Lessee shall pay to the Lessor the sum of one-third of the original bonus.

Extension Payment. If Allarity and/or its Affiliates or sublicensees have not achieved Successful Completion of the first Phase 2 Clinical Trial of the Product prior to December 31, 2022, then, in Allarity’s sole discretion, it may notify Eisai of its intention to continue Development activities of the Compound. In the event that Eisai and Allarity mutually agree to such continued Development activities by Allarity, Allarity shall pay a one-time payment to Eisai of [***] U.S. Dollars (the “Extension Payment”) within thirty (30) days following December 31, 2022. Notwithstanding the foregoing, in the event that Allarity has not enrolled and dosed at least thirty (30) patients with the first dose of cancer drug E7449 in the ongoing Phase 2 Ovarian Cancer Clinical Trial by July 1, 2022 then the Extension Payment shall become due and payable in full by July 30, 2022. 2) Section 14.2(f)(i) of the Original Agreement, “Eisai Right of Termination for Development”, is hereby amended and restated in its entirety as follows:

Extension Payment. The Company shall pay to the Executive the sum of $500,000, subject to applicable deductions and withholding, within ten (10) business days of the execution and delivery of this Letter Agreement.

Extension Payment. If OV and/or its Affiliates or sublicensees have not achieved Successful Completion of the first Phase 2 Clinical Trial of the Product prior to the fourth (4th) anniversary of the Effective Date, then, in OV’s sole discretion, it may notify Eisai of its intention to continue Development activities of the Compound. In the event that Eisai and OV mutually agree to such continued Development activities by OV, OV shall pay a one-time payment to Eisai of [***] (the “Extension Payment”) on the fourth (4th) anniversary of the Effective Date.

Extension Payment. CR Financial Holdings, Inc. and CHLM Sponsor LLC, or their affiliates or designees (the “Contributors”), have agreed to pay Shareholder $0.04 per share for each one-month extension (the “Extension Payment”) for each Share that is not redeemed during the Term by wire of the Extension Payment to an account designated for such purpose in writing by Shareholder. With respect to each Extension Payment, the Contributors shall wire the Extension Payment to Shareholder on or prior to the applicable monthly termination date.

Extension Payment. Allarity and Eisai desire to extend the timeframe for ▇▇▇▇▇▇▇▇’ s Successful Completion of the first Phase 2 Clinical Trial of the Product beyond December 31, 2022. In consideration of this extended timeframe, and ▇▇▇▇▇▇▇▇ not achieving the minimum patient enrollment, by July 1, 2022, set out in the Second Amendment, ▇▇▇▇▇▇▇▇ agrees to pay a one-time payment to Eisai of One Million Two Hundred and Fifty Thousand U.S. Dollars ($1,250,000) (the “Extension Payment”) as follows: (i) Two hundred and fifty thousand dollars ($250,000) (which has already been paid); and (ii) One hundred and fifty thousand dollars ($150,000) on or before May 1, 2024; and (iii) Eight Hundred and Fifty Thousand Dollars ($850,000) upon completion of a ten-million-dollar capital raising campaign, expected to take place before the end of May 2024, but in no event later than September 1, 2024.

Extension Payment. Borrower shall pay $24,714.76 to be paid in installment payments as follows: $6,178.69 on March 1, 2011; $6,178.69 on April 1, 2011; $6,178.69 on May 1, 2011; and $6,178.69 on June 1, 2011 (“Extension Payments”). The Extension Payments will be deemed made as of Closing Date. Borrower’s failure to make any of the Extension Payments when due shall be a default under this Agreement and under the Loan Documents.

Extension Payment. (a) Sponsor and Purchaser acknowledge that Purchaser’s deadline to complete an initial business combination pursuant to the terms of the Purchaser Charter expires on January 29, 2023 (the “Initial Deadline”), unless otherwise extended in accordance with the Purchaser Charter. (b) Subject to Section 2(d), Sponsor and Purchaser hereby covenant and agree to take (or to cause its affiliates or designees to take) all actions necessary to fulfill the conditions required in order to extend the Initial Deadline by a six (6) months or such shorter period as shall be mutually agreed by Purchaser, Sponsor, and the Company in accordance with the Merger Agreement (the “Extension”), including, without limitation, to make payment to one or more non-redeeming shareholders of Purchaser, the amount of which reasonably determined by Purchaser, Sponsor, in consultation with Company (the “Extension Payment”) in connection with such Extension (which payment shall take the form of a non-interest bearing loan repayable only in cash), all as reasonably requested by Company. (c) Sponsor hereby represents, warrants and covenants to Company that, as of the date by which the Extension Payment is required to be made (the “Extension Payment Date”), Sponsor (or its affiliates or designees) will have ready access to sufficient capital available to carry out its obligations under this Section 2 hereof. (d) Notwithstanding anything to the contrary set forth herein, in no event shall the Sponsor or the Purchaser be obligated to make the Extension Payment or otherwise effect the Extension unless, as of the Extension Payment Date: (i) the Merger Agreement is in full force and effect; (ii) there shall have been no material breach of the terms or conditions of the Merger Agreement by the Company or any other party thereto (other than the Purchaser), and (iii) no Material Adverse Effect shall have occurred and remained uncured on the Target Companies, taken as a whole that has not been waived by the Purchaser pursuant to the Merger Agreement. (e) Any Claim by the Company hereunder seeking to enforce the specific terms or provisions set forth in this Section 2, or which seeks to recover any damages as a result of a violation or alleged violation of this Section 2, shall be limited, in its entity, to the amount of the Extension Payment (and shall be subject, in all cases, to the terms of Section 4(e)), in the even that of any Claims against the Purchaser).